$ALNY

Alnylam Pharmaceuticals Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$126.78 โ–ผ-0.236%

Last Close

VOLUME

536,433

DAY RANGE

124.83 - 127.83

52 WEEK

117.58 - 212

Join Discuss about ALNY with like-minded investors

profile
@CarlosH-carvan #ivtrades
recently

$ALNY next week

90 Replies 13 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@ivtrades-Chris #ivtrades
recently

1375 $ALNY May22 180 Calls $12.733 (CboeTheo=11.44) ASKSIDE [MIAX] IV=53.4% +7.2 MPRL 1 x $9.60 - $14.00 x 20 PHLX ISO/AUCTION - OPENING Vol=1375, OI=129,

68 Replies 15 ๐Ÿ‘ 6 ๐Ÿ”ฅ

profile
@CarlosH-carvan #ivtrades
recently

$ALNY APr14 180C

69 Replies 14 ๐Ÿ‘ 13 ๐Ÿ”ฅ

profile
@marketjay #marketassasins
recently

Finally was able to dive into the names from earlier best opportunity that I like is ALNY but this is not a technical opportunity, this is a fundamental stand point and is contingent on FDA approval which looks strong and likely

95 Replies 8 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@marketjay #marketassasins
recently

unfortunately I'm a bit tied up so no intraday catalyst but my early scan on names I was potentially looking at were RDWR, ALNY, ORA, CERN with good set ups

92 Replies 8 ๐Ÿ‘ 11 ๐Ÿ”ฅ

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Thursday, October 28, 2021 Futures Up/Down % Last Dow 54.00 0.15% 35,443 S&P 500 11.25 0.26% 4,556 Nasdaq 74.50 0.47% 15.662 U.S. futures are looking at a rebound after a late day swoon erased record gains for stocks, as markets again await another earnings barrage, with yesterday and today the two busiest days of the quarter. Drama out of Washington D.C. also adding to the volatility as investors remain hopeful on a spending bill. As for Wednesday, a midday all-time high for the Nasdaq 100 was marred by a late day sell-off in U.S. stocks, as the S&P 500 and Dow each retreated from records set just the previous day, led by weakness in energy stocks as oil prices tumbled from 7-year highs and long-dated Treasury yields also slumped, with the 30-year falling as much as 10bps below 2%. Corporate earnings have generally been better-than-expected, but constant reminders about rising costs, supply-chain issues, and labor shortages on conference calls brings into question the strength of markets going forward. Couple that with expectations for the Fed to begin its asset tapering plans in November and chances of interest rate hikes in mid-2022 to help prevent inflation getting further out of hand remains a market concern. Shares of Dow components McDonaldโ€™s, Coca-Cola and Microsoft rallied behind strong earnings. In fact, the Nasdaq outperformed behind large cap winners (TSLA, GOOGL MSFT, AMZN), though breadth was decisively negative and SmallCaps plunged with the Russell 200 falling nearly 2%. President Bidenโ€™s infrastructure and social-spending plans still remain โ€œup-in-the-airโ€ which also adds uncertainty. In Asian markets, The Nikkei Index fell about 1% to 28,820, the Shanghai Index slipped -1.23% to 3.518 and the Hang Seng Index dipped about -0.25% to 25,555. In Europe, the German DAX is down -0.15% at 15,680, while the FTSE 100 is also down roughly -0.2% at 7,240. Market Closing Prices Yesterday The S&P 500 Index dropped -23.11 points, or 0.51%, to 4,551.68 The Dow Jones Industrial Average fell -266.19 points, or 0.74%, to 35,490.69 The Nasdaq Composite little changed, or 0.00%, to 15,235.84 The Russell 2000 Index declined -43.58 points, or 1.90% to 2,252.49 Events Calendar for Today 8:30 AM ET Weekly Jobless Claimsโ€ฆest. 290K 8:30 AM EST Continuing Claimsโ€ฆest. 2.415M 8:30 AM ET Gross Domestic Product (GDP) for Q3-Aโ€ฆest. 2.7% (down from prior) 8:30 AM ET GDP Consumer Spending for Q3-Aโ€ฆprior month 12.0% 8:30 AM ET GDP Price Deflator for Q3โ€ฆest. 5.5% 8:30 AM ET Core-PCE Prices Advance for Q3โ€ฆest. 4.5% 10:00 AM ET Pending Home Sales MoM for Septemberโ€ฆest. 0% 10:30 AM ET Weekly EIA Natural Gas Inventory Data 11:00 AM ET Kansas City Fed Manufacturing for October 1:00 PM ET U.S. to sell $62 bln 7-year notes Earnings Calendar: Earnings Before the Open: AB, ABMD, ADS, AEP, AGCO, ALNY, AMT, AOS, ATI, BAX, BC, BSIG, BTU, CARR, CAR, CBRE, CBZ, CFR, CG, CMCO, CMCSA, CMS, CNX, COLB, CONE, COOP, COR, CWT, DBD, EME, EXP, FCN, GPI, GVA, HBAN, HSY, IBP, ICE, ITW, KBR, KDP, KEX, LECO, LH, LKQ, MA, MCO, MDD, MO, MRK, NEM, NLSN, NOC, OSK, OSIS, OSTK, PBF, RGEN, RLGY, RS, SAH, SAIA, SNDR, SWI, SWK, TAP, TFX, TPX, TREE, TW, TXT, VC, VLY, WEX, WST, XEL, YUM Earnings After the Close: AAPL, ABCB, ACHC, AGL, AMZN, ASPN, ATEN, ATR, AVT, AX, BIO, BY, CDNA, CHE, COHU, COLM, CPT, CUZ, CWST, DECK, DVA, DXCM, EB, EMN, FISI, FTDR, FTV, GILD, HIG, HUBG, LOPE, LPLA, LTC, NGRC, MHK, MMSI, MPWR, MSTR, NATI, NXGN, PEB, POWI, PSB, PTCT, QUMU, RMD, RSG, SBCF, SBUX, SGEN, SKX, SKYW, SM, SPNE, SSNC, SYK, TEX, TXRH, VCRA, VRSN, WDC, WRAP, WRE, X, ZEN Macro Up/Down Last Nymex -1.61 81.05 Brent -1.37 83.21 Gold -2.10 1,801.20 EUR/USD -0.0006 1.1598 JPY/USD -0.23 113.57 10-Year Note +0.012 1.541% Sector News Breakdown Consumer eBay Inc. (EBAY) 3Q adj EPS $0.90 vs est. $0.89 on revs $2.5B vs est. $2.46B; guides 4Q adj EPS $0.72-0.76 vs est. $1.00, sees 4Q revs $2.57-2.62B vs est. $2.65B; raising estimated FY share buyback from $5.0B to $7.0B Ford Motor (F) announces resumption of stock dividend in 4q; 3Q adj EPS $0.51 vs est. $0.27 on revs $35.7B vs est. $32.5B; expects cash flow over current planning period to be more than sufficient to fund growth, announces resumption of regular stock dividend in 4Q; no changes to FY adj FCF guide of $4.0-5.0B Boot Barn (BOOT) Q2 EPS $1.25 vs est. $0.93 on revenue $312.7M (+67.1% vs 2Q19) vs est. $291M, same-store sales +61.7% YoY, +53.6% vs 2019; sees new unit growth 10% in FY22; named Jim Watkins as CFO with current CFO Greg Hackman continuing as VP and COO Churchill Downs (CHDN) 3Q EPS $1.57 vs est. $1.47 on revs $393Mm vs est. $406.8Mm Fresh Del Monte Produce Inc. (FDP) said it is raising prices on bananas, pineapples and fresh-cut fruit in response to unprecedented market conditions and inflationary pressures being felt across all industries iRobot (IRBT) Q3 EPS $1.67 vs. est. $0.70; Q3 revs $440.7M vs. est. $417.04M; cuts FY21 non-GAAP EPS view to $1.15-$1.74 from $2.25-$3.15 (est. $2.70) and lowers FY21 revenue view to $1.56B-$1.59B from $1.55B-$1.62B (est. $1.58B) Noodles (NDLS) Q3 adj EPS 12c vs est. 9c on in-line revenue $125.1M with digital sales 52% of total revs; system-wide comp sales +16.3% vs est. +14.3%, avg unit volume $1.38M, +16% YoY; now sees 7-9 new restaurants in 2021, down from prior outlook for 10-15; anticipates system-wide unit growth of at least 8% next year Oโ€™Reilly Auto (ORLY) Q3 EPS $8.07 vs. est. $7.18; Q3 sales $3.48B vs. est. $3.3B; gross profit margin 52.3% vs. 52.4% y/y; raises year rev outlook to $12.9B-$13.2B from prior $12.3B-$12.6B (est. $12.73B) Sleep Number (SNBR) 3Q EPS $2.22 vs est. $1.44 on revs $640Mm vs est. $587.1Mm; sees FY EPS $7.25 vs est. $7.15; Spirit Airlines (SAVE) Q3 adj EPS ($0.69) was a narrower loss than est. ($1.02) on in-line revs $922.6M; load factor 77.6%, capacity +3.5% vs 3Q19; is slowing the pace to push back to full fleet utilization, expects to produce 53B-55B available seat miles in 2022 VICI Properties (VICI) 3Q adj FFO/shr $0.45 on revs $375.7Mm; guides FY adj FFO/shr $1.7901.80 vs est. $1.84 Wyndham Hotels (WH) 3Q EPS $1.09 vs est. $0.91 on net revs $463Mm vs est. $463Mm; guides FY RevPAR growth about 43%, sees fee-related and other revs $1.21-1.23B; guides FY adj EPS $2.93-3.03 vs est. $2.69 Yum China (YUMC) Q3 adj EPS $0.22 vs. est. $0.31; Q3 revs $2.55B vs. est. $2.51B; qtrly total system sales increased 1% year over year, with increases of 1% at both KFC and Pizza Hut, excluding f/x; increasing gross new stores target to over 1,700 in 2021; expect that covid-19, especially the delta variant outbreaks, will continue to affect consumer behavior and impact our same-store sales recovery. Solo Brands, Inc. (DTC) prices 12.9M share IPO at $17.00 per share Scientific Games Corp (SGMS) announces sale of lottery business to Brookfield business partners for $6.05 billion; deal consisting of $5.825 bln in cash & an earn-out of up to $225 mln based on achievement of certain ebitda targets in 2022 & 2023 Energy, Industrials & Materials Allison Transmission (ALSN) 3Q EPS $0.89 vs est. $0.90 on revs $567Mm vs est. $584Mm; guides FY sales $2.325-2.4B vs est. $2.36B Flowserve Corp. (FLS) 3Q adj EPS $0.29 vs est. $0.40 on revs $866.1Mm vs est. $899Mm; guides FY revs down 2-4% vs est. -2.3%, sees FY EPS $1.45-1.65 (was $1.40-1.45) vs est. $1.58, sees CAPEX $70-80Mm vs prior $65Mm Kraton (KRA) Q3 adj EPS $0.98 vs. est. $0.79; Q3 revs $526.9M vs. est. $459.1M; Polymer segment operating income of $43.8 million, compared to an operating loss of $5.1 million YoY; Chemical segment operating income of $35.7M, compared to an operating loss of $401.7M YoY Sunnova Energy (NOVA) Q3 EPS ($0.25) vs est. ($0.13) on revenue $68.9M vs est. $67.4M; reaffirmed FY21 view for adj EBITDA $80M-$85M, customer additions 55k-58k; set FY22 guidance for adj EBITDA $117M-$137M, customer additions 83k-87k Tronox Holdings (TROX) Q3 adj EPS $0.72 vs. est. $0.64; Q3 revs rose 29% to $870M vs. est. $905.3M United Rentals (URI) 3Q adj EPS $6.58 vs est. $6.80 on revs $2.6B vs est. $2.58B; guides FY revs $9.6-9.75B vs est. $9.6B, sees FY adj EBITDA $4.325-4.4B vs est. 4.3B Financials Aflac (AFL) Q3 adj EPS $1.53 vs. est. $1.32; Q3 revs $5.2B vs. est. $5.34B; in yen terms, Aflac Japanโ€™s net premium income was ยฅ323.1 bln for quarter, or 4.0% lower than a year ago AvalonBay (AVB) Q3 core FFO $2.06 vs est. 1.97, EPS $0.56 vs est. $0.77, same-store sales +1.2%; sees Q4 core FFO $2.19-$2.29 vs est. $2.11, raised FY core FFO view to $8.18-$8.28 from $7.92-$8.12 CyrusOne Inc. (CONE) 3Q adj FFO/shr $1.02 vs est. $0.99 on revs $304.1Mm vs est. $290.4Mm; guides FY revs $1.18-1.2B vs est. $1.17B Invitation Homes (INVH) Q3 core FFO 38c/shr vs est. 36c, EPS 12c vs est. 10c, revenue $510M vs est. $497.8M; same-store NOI +11.9% YoY on same-store revs +7.9%; raised FY21 core EPS view to $1.49 at midpoint from $1.44, adj FFO ro $1.28 at midpoint from $1.24 Lending Club (LC) Q3 EPS $0.26 vs est. $0.03 on revenue $246.2M vs est. $221.2M; sees Q4 revs $240M-$250M vs est. $235.7M, loan originations $2.8-$3B; raised FY view for revenue to $796M-$806M from $750M-$780M Raymond James (RJF) Q4 EPS $2.06 vs. est. $1.71; Q4 revs $2.7B vs. est. $2.54B; quarter-end records for client assets under administration of $1.18 trillion, financial assets under management of $191.9B, and net loans at Raymond James Bank of $25B The SEC asked at least one asset manager not to proceed with plans for a leveraged bitcoin exchange-traded fund, according to a person familiar with the matter. The SEC indicated it wants to limit new bitcoin-related products to those that provide unleveraged exposure to bitcoin futures contracts, such as the ProShares Bitcoin Strategy exchange-traded fund, which was launched last week, the person said. https://on.wsj.com/3GvG2qg Healthcare Align Technology (ALGN) 3Q adj EPS $2.87 vs est. $2.60 on revs $1.02B vs est. $978Mm; guides FY revs $3.9-3.95B vs est. $3.94B; says clinical study validates benefits of the Itero Element 5D imaging system Alnylam (ALNY) reports positive topline 18-month results from Helios-a phase 3 study of Vutrisiran in patients with HATTR amyloidosis with polyneuropathy BioMarin (BMRN) Q3 GAAP EPS loss (-$0.20) vs. est. loss (-$0.25); Q3 revs $408.7M vs. est. $435.32M; Lower Kuvan product revenues primarily due to generic competition due to the loss of exclusivity in the U.S.; Lower Aldurazyme product revenues due to timing of product fulfillment to Genzyme Edwards LifeSciences (EW) Q3 EPS $0.54 vs. est. $0.53; Q3 revs $1.3B vs. est. $1.32B; sees FY21 adjusted EPS at high end of $2.07-$2.27 (est. $2.26) and reaffirms FY21 revenue view $5.2B-$5.4B (est. $5.32B); TAVR sales grew 15%; underlying 14%; U.S. TAVR sales grew 12%; OUS approximately 20% Encompass Health (EHC) Q3 adj EPS $1.03 vs. est. $1.06; Q3 revs $1.28B vs. est. $1.31B; cuts FY21 adj EPS view to $4.23-$4.38 from $4.32-$4.47 and lowers FY21 revenue view to $5.08B-$5.13B from $5.1B-$5.25B (est. $5.18B) Molina Healthcare (MOH) Q3 adj EPS $2.83 vs. est. $2.79; Q3 revs $7.04B vs. est. $6.79B; backs FY21 EPS view of no less than $13.25 vs. est. $13.38 and backs FY21 revenue view of no less than $27.5B vs. est. $26.97B; consolidated MCR for Q3 was 88.9%, compared to 85.9% in the third quarter of 2020 Teladoc (TDOC) Q3 EPS loss (-$0.53) vs. est. loss (-$0.65); Q3 revs $521.66M vs. est. $516.6M; Q3 visits topped 3.9M, 37% higher than Q3 2020; sees Q4 EPS loss (73c)-(53c) vs. est. loss (69c); sees Q4 revs $536M-$546M vs. est. $539.74M; sees Q4 total visits 3.9M-4.1M

132 Replies 8 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@dros #droscrew
recently

Upgrades 10/4: $ALNY $BTU $DD $JBT $LUV $ROP $SJI $UNP . Downgrades 10/4: $AKAM $EQC $GWRE $IDA $IIVI $MMM $OMER $TSCO $VERX $WISH $XLRN

135 Replies 8 ๐Ÿ‘ 11 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

$ALNY now with buyers of 1,300 December $190 calls for $19.90, adjusting the Sept. $185 calls Held the 55-EMA into this recent pullback but work to do to get back into value > $195

55 Replies 10 ๐Ÿ‘ 6 ๐Ÿ”ฅ

profile
@CarlosH-carvan #ivtrades
recently

$ALNY raised $175/$235

82 Replies 6 ๐Ÿ‘ 13 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

$ALNY earnings in the morning

55 Replies 7 ๐Ÿ‘ 8 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

out TDC and MTCH calls. bought more shares in ENGMF CLPT NNOX MELI ALNY UI and little more TMDX

54 Replies 6 ๐Ÿ‘ 15 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

up 50% on the $ALNY march calls i bought yesterday already

76 Replies 10 ๐Ÿ‘ 8 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

$ALNY good pick up yesterday

43 Replies 10 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

alny arwr psnl

139 Replies 7 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

could boost alny tho

91 Replies 10 ๐Ÿ‘ 7 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

whos riding with me > @Benlax said: $ALNY get long

83 Replies 15 ๐Ÿ‘ 12 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

$ALNY get long

125 Replies 10 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

$ALNY moving

148 Replies 10 ๐Ÿ‘ 6 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

anyone that wanted in $ALNY prob a good spot here

126 Replies 7 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

U another nice print ahead of ER dont think they got the multiple room to move up a lot but hopefully something good out it CRWD getting some selling and chart looking like it could roll over sklz buying falling off some after big move today, expected nice print for SE i think SE hits 500b in the next 3 years easy another nice print on tdoc chart wants higher for sure nice print on okta solid chart there too niceeee SPOT print into sell off thats what we want to see ew V with continued selling and the lowest print in a long time no plaid no buying i guess pags ugly too, sold my may calls there today for a little win nari improving, nothing like it was before its big run but getting back up there nice print on ups today big print on ALNY today nice round bottom there both SSPK and STPK long good and trending up stic looks ugly, still doing nothing, wonder if this barkbox merger fails or something great prints on BILI PDD and VIPS others not so much but those three look really good

125 Replies 14 ๐Ÿ‘ 15 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

$ALNY breaking out its flag here

131 Replies 7 ๐Ÿ‘ 9 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

alny is a good one to consider if it rests a bit after its huge run

100 Replies 12 ๐Ÿ‘ 9 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

another day another 5%+ for $ALNY

103 Replies 11 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

nvcr is a high growth med tech, gwph is a super underpriced but doesnt get much love has a few approved drugs most notably the only fda approved cbd drug, alny has a bunch of approved rna thearuptics and is still pretty cheap so good play on genetics

50 Replies 12 ๐Ÿ‘ 13 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

ALNY GWPH PSNL EXAS NVCR

96 Replies 9 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

$ALNY cant stop

125 Replies 13 ๐Ÿ‘ 7 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

$ALNY positive data out today

66 Replies 10 ๐Ÿ‘ 7 ๐Ÿ”ฅ

profile
@Benlax #droscrew
recently

Some good names here that could preannounce Own $GWPH $ALNY Like $NBIX $SRPT

41 Replies 6 ๐Ÿ‘ 7 ๐Ÿ”ฅ

TR
@TraderJack #ivtrades
recently

Your guys can buy $AZN, $BMRN, $ALNY, $DVAX, $EBS, and $NBIX, these are the potential contractors for my vaccine. However, be careful that some of them will drop hard if they does not get my vaccine contracts...who will get the final deal is my insider information...secret..

42 Replies 10 ๐Ÿ‘ 14 ๐Ÿ”ฅ

Key Metrics

Market Cap

15.31 B

Beta

0.73

Avg. Volume

0.95 M

Shares Outstanding

120.81 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTROยฎ (patisiran), GIVLAARIยฎ (givosiran), and OXLUMOโ„ข (lumasiran) and Leqvioยฎ (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.

CEO: John Maraganore

Website:

HQ: 675 W Kendall St Cambridge, 02142-1168 Massachusetts

Related News